CLDI Calidi Biotherapeutics, Inc.
Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1855485 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY19.9%
TTM EPS YoY192.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-373.6%
ROA-163.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets70.5%
Debt / equity0.41x
Current ratio1.27x
Interest coverage-252.18x
Cash quality & payout
Operating cash flow / net income0.99x
Accruals ratio-1.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $9.74M | $8.88M |
| SG&A expense | $10.50M | $12.90M |
| Operating income | -$20.24M | -$21.78M |
| Interest expense | $100,000 | $700,000 |
| Pretax income | -$20.05M | -$22.20M |
| Income tax | $15,000 | $14,000 |
| Net income | -$19.91M | -$22.14M |
| EBITDA | -$18.59M | -$20.24M |
| EPS (basic) | -5.95 | -35.70 |
| EPS (diluted) | -5.95 | -35.70 |
| Weighted avg. shares (diluted) | 4,302 | 667 |
| Balance sheet | ||
| Cash & equivalents | $5.82M | $9.81M |
| Current assets | $6.26M | $10.23M |
| PP&E, net | $781,000 | $869,000 |
| Total assets | $8.86M | $14.18M |
| Current liabilities | $3.94M | $9.50M |
| Short-term debt | $90,000 | $3.22M |
| Long-term debt | $600,000 | $600,000 |
| Total debt | $690,000 | $3.82M |
| Total liabilities | $5.10M | $12.21M |
| Shareholders' equity | $3.76M | $1.53M |
| Net debt | -$5.13M | -$5.99M |
| Shares outstanding | 451,076 | 1.73M |
| Cash flow statement | ||
| Operating cash flow | -$21.29M | -$19.69M |
| Investing cash flow | -$170,000 | -$16,000 |
| Financing cash flow | $17.46M | $27.36M |
| Depreciation & amortization | $1.65M | $1.53M |
| Stock-based compensation | $2.11M | $2.96M |
Free plan shows the latest 2 periods; Pro shows all 4 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.